Literature DB >> 3314409

Controversies in plastic surgery: suction-assisted lipectomy (SAL) and the hCG (human chorionic gonadotropin) protocol for obesity treatment.

T Vogt, D Belluscio.   

Abstract

The advent of SAL (suction-assisted lipectomy) has dramatically increased the number of obese patients coming to our consultation offices. Despite several articles suggesting a conservative approach to fat suction, some reports insinuate that SAL might be a useful tool for obesity treatment. This hypothesis is refuted by a vast body of evidence that concludes that the adipose tissue may regenerate in adult humans. Therefore, surgical procedures are not advised as the method of choice to manage the disease. On the other hand, the terms obesity and being overweight may not be interchangeable. Obesity may be a disease whereas being overweight is a sign of the disease. Consequently, proper preoperative selection of candidates for SAL becomes mandatory. The hCG (human chorionic gonadotropin) method for obesity treatment appears to be a complete program for the management of obesity. It contains pharmacologic, dietetic, and behavior modification aspects in a 40-day course of treatment. Some data suggest hCG to be lipolytic, thus explaining former clinical observations regarding body fat redistribution in treated patients. hCG commercial preparations contain beta-endorphin, an opioid peptide linked to mood behavior. This article speculates on the possible actions of the complex hCG beta-endorphin in the neuromodulation of mood and energy metabolism. The method comprises a behavior modification that helps in handling the patient better. There are some correlations between a current behavior modification program and the basic guidelines contained in the hCG protocol. Thus, the hCG method appears to be a reasonable alternative in the management of a long-standing, unsolved problem of human metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314409     DOI: 10.1007/BF01575502

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  237 in total

1.  The physiology of motivation.

Authors:  E STELLAR
Journal:  Psychol Rev       Date:  1954-01       Impact factor: 8.934

2.  Sexual differentiation; Factor determining forms of obesity.

Authors:  J VAGUE
Journal:  Presse Med       Date:  1947-05-24       Impact factor: 1.228

3.  The hypothalamic control of food intake in rats.

Authors:  G C KENNEDY
Journal:  Proc R Soc Lond B Biol Sci       Date:  1950-11

4.  Adipose tissue regeneration following lipectomy.

Authors:  I M Faust; P R Johnson; J Hirsch
Journal:  Science       Date:  1977-07-22       Impact factor: 47.728

5.  Metabolic effects of human chorionic gonadotropin (HCG) in rats.

Authors:  R Fleigelman; G H Fried
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

Review 6.  The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides.

Authors:  M Ferin; D Van Vugt; S Wardlaw
Journal:  Recent Prog Horm Res       Date:  1984

7.  Endogenous opiates and energy balance.

Authors:  A Mandenoff; F Fumeron; M Apfelbaum; D L Margules
Journal:  Science       Date:  1982-03-19       Impact factor: 47.728

8.  Weight reduction by fasting and semistarvation in morbid obesity: long-term follow-up.

Authors:  E J Drenick; D Johnson
Journal:  Int J Obes       Date:  1978

9.  Anterior hypothalamic lesions impair reflex bradycardia selectively in rats.

Authors:  E Miyajima; R D Buñag
Journal:  Am J Physiol       Date:  1985-06

10.  The prevalence of obesity and thinness in children from a lower socioeconomic population receiving comprehensive health care.

Authors:  R H DuRant; D S Martin; C W Linder; W Weston
Journal:  Am J Clin Nutr       Date:  1980-09       Impact factor: 7.045

View more
  1 in total

1.  The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis.

Authors:  G K Lijesen; I Theeuwen; W J Assendelft; G Van Der Wal
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.